Regeneron (REGN) Tops Q2 EPS by 104c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Grand Canyon Education places CFO on leave amid stock trade probe
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
Regeneron Reports Second Quarter 2017 Financial and Operating Results
August 3, 2017 6:30 AM EDTTARRYTOWN, N.Y., Aug. 3, 2017 /PRNewswire/ -- Â
Second quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 11% to $919 million versus second quarter 2016 Second quarter 2017 EYLEA global net sales(1) increased 11% to $1.46 billion versus second quarter 2016 Raised estimated full year 2017 EYLEA U.S. net sales growth guidance to approximately 10% over 2016 Kevzara® (sarilumab) approved by FDA and European Commission for adults with moderately to severely active rheumatoid arthritisRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2017 and provided a business... More
